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The recent discovery of the role played by gut microbiota on the control of metabolic disease opens novel routes 
for the identification of the causes of type 2 diabetes and obesity. This paradigm could explain the infiltration, by 
innate and adaptive immune cells, of the adipose tissue, liver, and islets of Langerhans which is responsible for the 
metabolic inflammation state that leads to impaired insulin action and secretion, and therefore, type 2 diabetes. 
The identification of the causal role of circulating lipopolysaccharides (LPS) and peptidoglycans in the 
development of metabolic inflammation, due to an increased intestinal permeability, led to the leaky gut 
hypothesis. In addition, whole live bacteria were found in metabolic tissues establishing a tissue microbiota which 
upon a fat-enriched diet becomes dysbiotic. The process of intestinal bacterial translocation was responsible for 
the onset of a leaky gut causal to the disease. The translocation of selective sets of intestinal bacteria to the blood 
could be identified. These blood bacterial 16SrRNA-DNA sequences are considered as biomarkers of the bacterial 
translocation process. An increased of the corresponding bacterial DNA concentration was predicting the 
occurrence of type 2 diabetes. Associated to the dysbiotic microbiota translocation, an impaired intestinal immune 
defense was identified as a cause of the selective leaky gut. The change in small intestine mucosal microbiota 
induced by a fat-enriched diet reduces the number of IL17-secreting CD4 T cells within the lamina propria of the 
intestine. This loss of IL17-secreting CD4 T cells is the consequence of an impaired capacity of intestinal antigen 
presenting cells to activate and trigger the expression of Retineic-acid-receptor-related orphan nuclear receptor 
gamma (RORγt) and the production of IL17 by CD4 T cells. Altogether, an impaired intestinal immune defense, 
notably the reduced differentiation of RORt expressing IL17-producing CD4 T cells, favors the onset of a leaky 
gut leading to the translocation of bacterial factors and live bacteria towards tissues triggering metabolic 
inflammation; insulin resistance and type 2 diabetes. Hence, the triggering of intestinal defense surrounding 
RORt pathway now appears as a potential target mechanism for the control of type 2 diabetes. 
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The last decade has demonstrated the importance of gut 
microbiota on the control of metabolic diseases through 
mechanisms that are currently been uncovered. More precisely, 
this relationship can explain the key deleterious role of 
metabolic inflammation described in insulin sensitive tissues 
such as the liver, adipose depots and muscles but can also 
explain the epidemic development of the disease. In 2025 
more than 350 million people will become type 2 diabetic with 
a doubling of this incidence in oriental countries. Hence, a 
“contagious” agent was suspected to explain such epidemic 
development. The commensal bacterial ecology from the gut 
was demonstrated to be dysbiotic in obese and type 2 diabetic 
humans and rodents and was representing a leading hypothesis 
to the epidemic development. 
 
The gut microbiota encompasses trillions of bacteria 
which are mostly [>90%] represented by two phyla, the 
Bacteroidetes and the Firmicutes. Actinobacteria and 
Proteobacteria, although minor, are also important phyla 
that play a role in the ecology of gut microbiota and its 
relationship with the host. Bacteria, along the digestive track 
are distributed according to gradients of pH and oxygen. 
Taxa able to live in a low pH and high pressure of oxygen 
are present starting from the stomach until the distal ileum, 
while at the entry into the proximal colon most of the 
microbial ecology is composed of anaerobic and fermenting 
bacteria. Another major player responsible for the control of 
gut microbiota ecology is the intestinal defense system which 
includes first, a mucus layer composed of mucin, proteins 
which gets thicker and sealer, as the microbiota develops 
along the intestine from the proximal to the distal intestinal 
track. Second, antimicrobial peptides are secreted by Paneth 
cells, i.e. defensins, which are natural antibiotics that 
eliminate bacteria from the mucus layer, which would not be 
allowed to survive close or within the mucus. Third, the 
immune system, including both the innate and the adaptive 
immune systems, shapes gut microbiota. The innate immune 
cells, including dendritic cells and macrophages, sample 
bacteria from the mucus layer and those that succeed in 
translocating from the lumen to the lamina propria of the villi. 
Bacterial antigen presentation by these innate immune cells 
leads to the activation of T lymphocytes. In addition, 
antibody-secretion specialized B cells, plasmocytes produce 
mg per day of immunoglobulins which are secreted within 
the intestine and targeted the gut microbiota. Altogether, the 
gut microbiota inherited mostly at birth from the mother and 
close relatives stabilizes around 2-3 years of age and remains 
under a symbiotic control with the host up until aging. 
Importantly, it is conceivable that the bacteria present in the 
upper digestive track have different metabolic features and 
therefore functions, when compared to those present in the 
colon. A major issue concerns the role played by the 
 
microbiota from the different intestinal segments on the 
control of energy metabolism. In physiological situations, the 
gut microbiota ensures digestive functions throughout the 
hydrolysis and fermentation of non-digestible nutrients such 
as dietary fibers into proprionic, butyric and lactic acids. The 
colonic fermenting bacteria are mostly handling this function. 
Gut microbiota also contributes to lipid emulsification through 
the production of dehydroxylated, sulfated or nitrosylated bile 
acids, the latters being important for the regulation of energy 
metabolism. Eventually, gut microbiota is also responsible for 
the synthesis of vitamins such as the B12. The overall role of 
gut microbiota is to induce the development of important 
functions and among them digestion and immunity. 
 
A dysbiotic gut microbiota was markedly observed in 
patients with metabolic diseases such as obesity and type 2 
diabetes. It is characterized by changes in the proportion of 
Firmicutes and Bacteriodetes along with an increased 
proportion of the Proteobacteria. Microbiota dysbiosis was 
demonstrated to be causally involved in the development of 
the disease. The colonization of a germ free mouse with the 
gut microbiota from a mouse in which metabolic disease and 
gut microbiota dysbiosis have been induced by a fat-enriched 
diet induced metabolic disease [1]. Ever since, physiological 
mechanisms were proposed which could explain the role 
played by gut microbiota. Among them, the control of bile 
acids [2], GLP-1 secretion [3], intestinal gluconeogenesis [4] or 
intestinal inflammation [5], are the most promising. However, 
out of these hypotheses, none could causally reconcile gut 
microbiota dysbiosis with metabolic inflammation i.e. tissue 
inflammation, and insulin resistance. A further mechanism 
was required. In 2007, we identified that increased plasma 
LPS concentrations, i.e. metabolic endotoxemia, was 
responsible for high-fat diet-induced metabolic inflammation 
leading to metabolic disease [6]. This mechanism was 
demonstrated by the mean of low rates of LPS infusion which 
triggered within a month glucose intolerance, hepatic insulin 
resistance, hepatic steatosis, and adipose tissue development 
while mice deleted for the LPS receptor, i.e. CD14, resisted 
the occurrence of metabolic diseases. We further showed that 
LPS could causally trigger the proliferation of adipocyte 
precursors and macrophages [7] through a mechanism requiring 
CD14 to detect the LPS moieties. More recently, we identified 
that bacterial 16SrRNA-DNA was also detected in a higher 
concentration in apparently healthy individuals which were 
predicted to become type 2 diabetic within the next 6-9 years 
[8]. A doubling of the 16SrRNA-DNA concentration 
significantly increased the incidence of type 2 diabetes. The 
sequencing of the 16SrRNA-DNA gene demonstrates that 
most of the bacterial DNA was from the Proteobacteria family 
which are LPS producing bacteria. Numerous mechanisms are 
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Figure 1. Targeting intestinal ROR/IL17 producing CD4 T cells to control metabolic disease. 
Gut microbiota dysbiosis induced by a high-fat diet impairs the capacity of the intestinal antigen 
presenting cells to induce the differentiation of IL17 producing CD4 T cells. This decrease in intestinal 
Th17 cells reduces the intestinal defense, in part through a decrease in the production of antimicrobial 
peptides, allowing an increase in bacterial translocation from intestine towards metabolic tissues. 
Bacterial determinants such as LPS, initiates the activation of immune system in metabolic tissues so 
that the production of inflammatory chemokines and cytokines trigger insulin resistance and to the 
development of metabolic disease. Targeting intestinal defense could be considered as a novel 
source of therapeutic perspectives. 
 
responsible for metabolic endotoxemia. Among them an 
increased intestinal permeability [9] and a change in LPS 
clearance are linked to a lowering of the circulating lipoprotein 
metabolism [10]. The increased bacterial DNA concentration in 
blood was linked to an increased translocation of intestinal 
bacteria towards the tissues including the blood through 
mechanisms [11] requiring and impaired intestinal recognition 
of bacterial determinants such as LPS and peptidoglycans by 
NOD1/2 and TLR4/CD14 receptors [12, 13]. Bacterial 
translocation is a naturally occurring mechanism that in some 
instances is dramatically increased such as in patients with 
HIV [14] or leaky gut [11, 13, 15]. Altogether, an impaired 
intestinal defense in type 2 diabetic patients was suggested to 
be responsible for the increased bacterial translocation, the 
establishment of a dysbiotic tissue microbiota [16] and hence an 
increased metabolic inflammation and the development of 
metabolic diseases. 
 
Recent data from the literature identified that tissue 
metabolic inflammation involved innate [17, 18] and adaptive 
immune systems [19, 20]. First, metabolic diseases were largely 
characterized by an infiltration of metabolic tissue such as 
adipose tissue by macrophages. Limiting the infiltration of 
macrophages in adipose tissue reduced the inflammatory 
profile and improved insulin sensitivity [17, 21, 22]. Some data 
also argued for a role of dendritic cells in the initiation or the 
maintenance of metabolic inflammation since the loss of 
weight reduced the number of infiltrating cells along with a 
decrease of pro-inflammatory adipokines in obese patients [23; 
24]. Ablation of dendritic cells in insulin-resistant mice, 
decreased inflammatory markers and normalized insulin 
sensitivity [25]. In addition, other innate immune cells, such as 
mast cells, infiltrated adipose tissue during metabolic disease 
[26] where these cells, through their MHCII, could present 
antigens and activate T lymphocytes. An important role of T 
lymphocytes in the development of metabolic disease was 
also demonstrated with the accumulation of inflammatory 
CD8 T lymphocytes in adipose tissue of obese mice [27]. 
Ablation of CD8 T lymphocytes decreased the adipose tissue 
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macrophages infiltration and improved metabolic parameters. 
Conversely, their adoptive transfer aggravated adipose 
inflammation while contrarily to CD8 T lymphocytes, the 
number of regulatory Foxp3+ CD4 T lymphocytes was 
decreased in adipose tissue of obese and insulin-resistant mice 
[28]. Transfer of regulatory T lymphocytes improved metabolic 
inflammation and insulin sensitivity by toning down the 
overall metabolic inflammatory process demonstrating the 
importance of not only innate immune cells but also of the 
adaptive immune system. Others lymphocytes might also be 
involved in the maintenance of metabolic inflammation such 
as NKT which recognize lipids in the context of CD1d [29] and 
B lymphocytes that the concentration is also increased in 
metabolic tissues following diet-induced obesity [30]. 
Altogether, activation, recruitment and infiltration of immune 
cells, within metabolic tissues, adipose depots and liver, lead 
to the secretion of immune factors such as cytokines that 
maintain a low-grade inflammatory tone and are deleterious 
for cellular insulin signaling leading to an impaired insulin 
action. 
 
However, the origin of the determinants responsible for 
the activation of the tissue immune system remained unclear. 
We hypothesized that the bacterial translocation, through 
the establishment of the tissue microbiota could be 
responsible [16, 31]. Therefore, features from the intestinal 
immune defense must have been altered in conditions of gut 
microbiota dysbiosis such as in response to a fat-enriched 
diet. We explored this hypothesis and identified changes in 
intestinal immunity before the onset of insulin resistance. A 
decrease  in the number of inflammatory IL17-producing 
CD4 T cells was observed in the lamina propria of the ileum 
after only 10 days of a fat-enriched diet and was maintained 
and even exacerbated after 30 days. Since RORt is the key 
transcription factor responsible for the differentiation of 
naïve CD4 T lymphocytes into Th17/22 differentiated 
lymphocytes, we quantified the RORt-expressing CD4 T 
lymphocytes and found them similarly reduced in the lamina 
propria of the high fat diet-fed mice after only 10 days. The 
corresponding deficient mice, i.e. without challenging them 
with a high fat diet, developed spontaneously insulin 
resistance, glucose intolerance and other metabolic features 
demonstrating the importance of this gene on the control of 
energy metabolism. The transfer of T cells isolated from 
RORt deficient mice into Rag1 deficient mice induced the 
development of metabolic disease, demonstrating the causal 
role of Th17 cells. This experiment demonstrated that an 
impaired Th17 cell production was sufficient to induce 
metabolic disease. However, we cannot rule out that other 
IL17-producing cells such as innate lymphoid cells type 3 
(ILC3) have no role. Few weeks after this transfer, mice 
spontaneously developed glucose intolerance and insulin 
resistance, which clearly demonstrated a pivotal protecting  
role for Th17 cells in the control of metabolic disease. In 
agreement with our results, a positive role for intestinal IL22, 
another cytokine produced in part by Th17 cells, was recently 
demonstrated for the control of metabolic disorders [32]. 
Furthermore, in HIV-infected human patients, who have a 
higher incidence of type 2 diabetes [33], a loss of IL22 
producing CD4 T cells was reported [34] and was associated 
with an increased bacterial translocation [14]. 
 
Since metabolic disease is associated with gut microbiota 
dysbiosis and since the adaptive and innate immune systems 
are in closed contact and influenced by microbiota [35], we 
speculated that changes in gut microbiota induced by a fat-
enriched diet would be responsible for the loss of intestinal 
IL17-producing cells. To causally incriminate gut microbiota 
dysbiosis, high-fat diet-fed mice were orally treated with a 
mixture of prebiotic and probiotic (synbiotic) known to 
modify gut microbiota dysbiosis and to improve high-fat 
diet-induced metabolic disease [36]. We first validated that a 
one-month synbiotic treatment drastically changed the ileum 
microbiota. We focused our attention on the ileum 
microbiota since the major drastic changes of the number of 
IL17-producing CD4 T cells observed were within the 
lamina propria of this intestinal segment. Furthermore, this 
is an intestinal location where images of bacterial 
translocation were clearly observed [13]. We observed that 
the synbiotic treatment prevented the loss of intestinal Th17 
and the development of high fat diet-induced metabolic 
disease. The dysbiotic microbiota was characterized by a 
reduction in the proportion of Porphyromonadaceae that was 
totally normalized by the synbiotic treatment along with the 
i mp ro ve men t  o f  a l l  me tabo l i c  pa ra me te r s .  T he 
Porphyromonadaceae are known to promote Th17 inducing 
pathways [37] as observed during periodontitis [38]. Therefore, 
their reduced frequency within the intestine could be linked 
to the reduced number of IL17 producing cells within the 
lamina propria of the small intestine.  Segmentous 
Filamentous Bacteria (SFB) are known to induce, at least in 
the mouse, the differentiation of Th17 cells [39; 40]. However, 
although their frequency was reduced by more than 90% in 
the intestine from prediabetic mice it was not restored by the 
synbiotic treatment whereas the number of IL17-producing 
CD4 T cells and the metabolic features were improved. 
Therefore, a change in SFB frequency was not responsible, 
in our experiment, for the increased IL17-producing CD4 T 
cells and the improved metabolic phenotype. We cannot rule 
out that a therapeutic strategy against metabolic disease 
could be derived from SFB aiming at restoring intestinal 
IL17 production. This still needs to be tested. Similarly, it 
can be suggested that the microbiota from other intestinal 
segments could be involved as well. Although, we do not 
have argument supporting this hypothesis, it cannot be ruled 
out. Then, to clearly demonstrate a causal role of the ileum 
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microbiota dysbiosis on the decrease number of intestinal 
Th17 cells, germ free mice were colonized with the microbiota 
isolated from the ileum of high-fat diet-fed mice treated or not 
with synbiotic. Conversely to the ileum microbiota from high-
fat diet-fed mice, ileum microbiota of symbiotic treated mice 
increased the number of intestinal Th17 and prevented the 
development of metabolic disease, showing that bacteria 
present in synbiotic-treated microbiota could induce intestinal 
Th17 cells. Interestingly, in addition to microbiota, viruses 
like bacteriophages could be involved, since the latters are 
requiring specific bacteria isotype to develop. Therefore, the 
viruses could be controlling IL17 producing cells, instead of 
bacteria, while the bacteria will just be required for the growth 
and production of the active viruses. This is again another 
hypothesis that needs to be explored. Another demonstration 
that intestinal Th17 are crucial for the protection against 
metabolic disease is that induction of experimental colitis, 
which induced intestinal Th17, prevented the development of 
metabolic disease. Peptostreptococcaceae, another intestinal 
bacterial family, was reported to be involved in the prevention 
of the development of colitis. Since we have observed an 
increase in this bacterial family under a fat enriched diet that 
is prevented by the symbiotic treatment, 
Peptostreptococcaceae would be a candidate involved in the 
loss of intestinal Th17 at the onset of metabolic disease. 
 
This complex ecology of bacteria could impact 
differentiation of intestinal Th17 by controlling antigen 
presenting cell functions. Transciptomic analysis revealed that 
high-fat diet-induced microbiota dysbiosis was associated 
with alteration of antigen presenting cells transcriptomic 
profiles suggesting an impaired capacity to activate T cells. In 
vitro, intestinal antigen presenting cells isolated from high-fat 
diet-fed mice were less able to produce cytokines, i.e. IL6 
IL12p40 involved in the differentiation and maintenance of 
Th17 cells, and to promote differentiation of naïve T cells into 
Th17. Overall, changes in ileum microbiota [induced by a fat-
enriched diet] could impair the ability of intestinal antigen 
presenting cells to promote Th17. This mechanism could 
explain the improvement of insulin resistance in human after 
a bariatric surgery, since this surgery is associated with 
dramatic changes in gut microbiota [41]. 
 
As a consequence of the decrease in IL17 produced by 
intestinal CD4 T cells, anti-microbial peptides could be altered 
such as Reg3 and Reg3 which expression decreased 
similarly to the loss of intestinal Th17. Alteration of mucosal 
protection could allow an increase in dysbiotic bacterial 
translocation towards metabolic tissues where deleterious 
bacteria could initiate metabolic inflammation. Interestingly, 
human studies from jejunal samples of obese subjects
without comorbidity, or suffering from obesity-related 
comorbidity, or diabetic, versus lean controls, showed that 
obesity is associated with T-cell-mediated inflammation and 
enterocyte insulin resistance [42]. Although, it could not be 
causally linked to the development of the disease, the authors 
identified an increased number of both innate and adaptive 
immune cells particularly CD8αβ T cells in the obese jejunum 
epithelium in association with an increase in inflammatory 
cytokines suggesting an intestinal inflammation. Importantly, 
the authors showed an increased Th17 cells in the lamina 
propria of obese patients with a mean body mass index over 45, 
which represents only a small subset of the overall obese 
patients where BMI are closer to 30-35. These patients could 
be also considered as late onset where the increased intestinal 
inflammation and enterocyte insulin resistance could be 
considered consequences to the disease. Moreover, human data 
are not available regarding the general obese patient population. 
 
Altogether, a change in gut immunity linked to gut 
microbiota dysbiosis is now considered as a novel cellular 
mechanism associated to metabolic disease. The intestine is a 
major player of energy homeostasis where the molecular 
crosstalk between intestinal cells and gut microbiota could be 
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